Pfizer Inc. is facing increasing financial strain as COVID-related revenues plummet to approximately $12 billion, prompting a notable decline in stock prices and investor confidence. Trading at a forward P/E ratio of 8.5, significantly lower than industry peers, the company is perceived as undervalued, yet analysts forecast a 9.52% drop in earnings per share for the upcoming quarter. In response to these challenges, Pfizer is pivoting towards scientific innovation and strategic acquisitions to stabilize its portfolio while grappling with a slowing growth outlook and expectations of lagging market performance.
“The print comes amid ongoing portfolio reshaping, including Pfizer’s recent decision to divest its equity stake in ViiV Healthcare.”
“PFE trades at just ~8.5x forward non-GAAP earnings, well below peers such as AbbVie, Merck, and Eli Lilly.”
“Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to invest in now. On January 27, Cantor Fitzgerald raised the firm’s price target on Pfizer to $27 from $24 and maintained a Neutral rating on the shares.”
“With 2026 guidance already established and only modest beat-and-raise potential anticipated, the firm expects a relatively quiet earnings call, shifting investor focus toward the timing and framing of VESPER-3 obesity data.”
“While the pandemic rocketed Pfizer to record heights … by 2023, COVID-related revenues had plummeted to approximately $12 billion, significantly impacting the company’s stock price.”
“To weather this storm, Bourla is betting the house on scientific innovation rather than consumer healthcare.”
“PFE also inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China.”
“Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open.”
“Estimates for Pfizer’s 2026 earnings have declined from $3.15 to $2.99 per share over the past 60 days.”
“It delivered a four-quarter earnings surprise of 35.33%, on average.”
“Pfizer will most likely maintain its 2026 financial guidance on the fourth-quarter conference call.”
“From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its five-year mean.”
.svg&width=160)